| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Feb 2026 | 5 Feb 2026 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended on 31st December 2025. Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025 (As Per BSE Announcement Dated on: 14/02/2026) | ||
| Board Meeting | 14 Nov 2025 | 6 Nov 2025 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 14th November 2025 at 05:00 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business: 1. To consider and approve the Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended 30th September 2025. 2. Any other business that may be necessary with the permission of Chairman. Considered and approved the financial results for the quarter and half year ended 30th September 2025 (As Per BSE Announcement Dated on 14.11.2025) | ||
| Board Meeting | 6 Sep 2025 | 6 Sep 2025 |
| This is to inform you under Regulation 30 and any other regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Board of Directors of the Company at its meeting held today i.e. Saturday, September, 06, 2025 inter-alia has taken the following decisions:- 1. The Board of Directors of the Company have considered and approved the Report of Board of Directors for the financial year ended as on March 31, 2025 under section 134 of the Companies Act, 2013. 2. The Board of Directors of the Company have considered and approved the Notice of 19th Annual General Meeting of the Company. 3. The Board has approved the day, date, time and calendar of events and Notice of 19th Annual General Meeting of the company to be held on Tuesday 30th September, 2025 at 11:30 AM, through Video Conferencing (VC)/Other Audio Visual Means (OAVM). * OTHER DETAILS AS PER ATTACHMENT | ||
| Board Meeting | 14 Aug 2025 | 6 Aug 2025 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve the Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter ended 30th June 2025. 2. Any other business that may be necessary with the permission of Chairman. We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended as on 30.06.2025 along with the Auditors limited review reports thereon (As Per BSE Announcement Dated on: 14/08/2025 | ||
| Board Meeting | 30 May 2025 | 22 May 2025 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 30th May 2025 at 05:30 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business: 1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2025. 2. Any other business that may be necessary with the permission of Chairman. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Board Meeting held today i.e. on Friday, 30th May, 2025, and have Considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended 31st March, 2025. The said Audited Financial Results were reviewed by Audit Committee and thereafter approved by the Board of Directors. (As Per BSE Announcement Dated on: 30/05/2025) | ||
| Board Meeting | 12 Mar 2025 | 12 Mar 2025 |
| Pursuant to Regulation 30 of SEBI (LODR), Regulations 2015, the Board of Directors at the meeting held on today March 12, 2025 have considered and appointed Ms. Harshita Aggarwal as the Company Secretary and Compliance Officer of the company w.e.f March 12, 2025. | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
